{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T00:19:33Z","timestamp":1784333973689,"version":"3.55.0"},"reference-count":66,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,3,17]],"date-time":"2022-03-17T00:00:00Z","timestamp":1647475200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,3,17]],"date-time":"2022-03-17T00:00:00Z","timestamp":1647475200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005847","name":"Health and Medical Research Fund","doi-asserted-by":"publisher","award":["COVID19F01"],"award-info":[{"award-number":["COVID19F01"]}],"id":[{"id":"10.13039\/501100005847","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Safety after the second dose of the SARS-CoV-2 vaccine remains to be elucidated, especially among individuals reporting adverse events after their first dose. This study aims to evaluate the impact of a delayed second dose on all-cause mortality and emergency services.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>A territory-wide, retrospective cohort of people who had completed two doses of mRNA (BNT162b2) or inactivated SARS-CoV-2 (CoronaVac) vaccine between February 23 and July 3, 2021, in Hong Kong was analyzed, with linkage to electronic health records retrieved from the Hong Kong Hospital Authority. Vaccine recipients were classified as receiving a second dose within recommended intervals (21\u201328 days for BNT162b2; 14\u201328 days for CoronaVac) or delayed. Study outcomes were all-cause mortality, emergency department (ED) visits, and unscheduled hospitalizations within 28 days after the second dose of vaccination.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Among 417,497 BNT162b2 and 354,283 CoronaVac second dose recipients, 3.8% and 28.5% received the second dose beyond the recommended intervals (mean 34.4 and 31.8 days), respectively. During the study period, there were &lt; 5 daily new cases of COVID-19 infections in the community. Delaying the second dose was not associated with all-cause mortality\u00a0(hazard ratio [HR] = 1.185, 95% CI 0.478\u20132.937, <jats:italic>P<\/jats:italic> = 0.714), risk of ED visit (HR = 0.966, 95% CI 0.926\u20131.008, <jats:italic>P<\/jats:italic> = 0.113), and risk of unscheduled hospitalization\u00a0(HR = 0.956, 95% CI 0.878\u20131.040, <jats:italic>P<\/jats:italic> = 0.294) compared to that within the recommended interval for CoronaVac recipients. No statistically significant differences in all-cause mortality\u00a0(HR = 4.438, 95% CI 0.951\u201320.701, <jats:italic>P<\/jats:italic> = 0.058), ED visit (HR = 1.037, 95% CI 0.951\u20131.130, <jats:italic>P<\/jats:italic> = 0.411), and unscheduled hospitalization\u00a0(HR = 1.054, 95% CI 0.867\u20131.281, <jats:italic>P<\/jats:italic> = 0.597) were identified between people who received a second dose of BNT162b2 within and beyond the recommended intervals.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>No significant association between delayed second dose of BNT162b2 or CoronaVac and all-cause mortality, ED visit, and unscheduled hospitalization was observed in the present cohort. Regardless of the recommended or delayed schedule for SARS-CoV-2 vaccination, a second dose of both vaccines should be administered to obtain better protection against infection and serious disease. The second dose should be administered within the recommended interval following the manufacturer\u2019s product information, until further studies support the benefits of delaying vaccination outweighing the risks.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12916-022-02321-4","type":"journal-article","created":{"date-parts":[[2022,3,17]],"date-time":"2022-03-17T01:02:43Z","timestamp":1647478963000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Impact of a delayed second dose of mRNA vaccine (BNT162b2) and inactivated SARS-CoV-2 vaccine (CoronaVac) on risks of all-cause mortality, emergency department visit, and unscheduled hospitalization"],"prefix":"10.1186","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6895-6071","authenticated-orcid":false,"given":"Carlos King Ho","family":"Wong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9418-7448","authenticated-orcid":false,"given":"Xi","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4412-2969","authenticated-orcid":false,"given":"Kristy Tsz Kwan","family":"Lau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1513-8726","authenticated-orcid":false,"given":"Celine Sze Ling","family":"Chui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9121-1959","authenticated-orcid":false,"given":"Francisco Tsz Tsun","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4836-7808","authenticated-orcid":false,"given":"Xue","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7602-9470","authenticated-orcid":false,"given":"Esther Wai Yin","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6275-1147","authenticated-orcid":false,"given":"Eric Yuk Fai","family":"Wan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5904-8322","authenticated-orcid":false,"given":"Ivan Chi Ho","family":"Au","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6297-7154","authenticated-orcid":false,"given":"Benjamin John","family":"Cowling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3939-564X","authenticated-orcid":false,"given":"Cheuk Kwong","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8242-0014","authenticated-orcid":false,"given":"Ian Chi Kei","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,3,17]]},"reference":[{"issue":"1","key":"2321_CR1","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1038\/s41541-021-00292-w","volume":"6","author":"NC Kyriakidis","year":"2021","unstructured":"Kyriakidis NC, L\u00f3pez-Cort\u00e9s A, Gonz\u00e1lez EV, Grimaldos AB, Prado EO. SARS-CoV-2 vaccines strategies: a comprehensive review of phase 3 candidates. NPJ Vaccines. 2021;6(1):28.","journal-title":"NPJ Vaccines"},{"issue":"9","key":"2321_CR2","doi-asserted-by":"publisher","first-page":"e28","DOI":"10.1056\/NEJMclde2101987","volume":"384","author":"SR Kadire","year":"2021","unstructured":"Kadire SR, Wachter RM, Lurie N. Delayed second dose versus standard regimen for COVID-19 vaccination. N Engl J Med. 2021;384(9):e28.","journal-title":"N Engl J Med"},{"key":"2321_CR3","first-page":"67","volume":"63","author":"T Tauh","year":"2021","unstructured":"Tauh T, Mozel M, Meyler P, Lee SM, Mas M. What is the evidence for extending the SARS-CoV-2 (COVID-19) vaccine dosing schedule. BC Med J. 2021;63:67\u201370.","journal-title":"BC Med J"},{"issue":"10277","key":"2321_CR4","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1016\/S0140-6736(21)00432-3","volume":"397","author":"M Voysey","year":"2021","unstructured":"Voysey M, Costa Clemens SA, Madhi SA, Weckx LY, Folegatti PM, Aley PK, et al. Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials. Lancet. 2021;397(10277):881\u201391.","journal-title":"Lancet"},{"issue":"10304","key":"2321_CR5","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1016\/S0140-6736(21)01699-8","volume":"398","author":"A Flaxman","year":"2021","unstructured":"Flaxman A, Marchevsky NG, Jenkin D, Aboagye J, Aley PK, Angus B, et al. Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002). Lancet. 2021;398(10304):981\u201390.","journal-title":"Lancet"},{"key":"2321_CR6","doi-asserted-by":"publisher","unstructured":"Zeng G, Wu Q, Pan H, Li M, Yang J, Wang L, et al. Immunogenicity and safety of a third dose of CoronaVac, and immune persistence of a two-dose schedule, in healthy adults: interim results from two single-centre, double-blind, randomised, placebo-controlled phase 2 clinical trials. Lancet Infect Dis. 2021. https:\/\/doi.org\/10.1016\/S1473-3099(21)00681-2. Online ahead of print.","DOI":"10.1016\/S1473-3099(21)00681-2"},{"issue":"4","key":"2321_CR7","doi-asserted-by":"publisher","first-page":"e3001211","DOI":"10.1371\/journal.pbio.3001211","volume":"19","author":"SM Moghadas","year":"2021","unstructured":"Moghadas SM, Vilches TN, Zhang K, Nourbakhsh S, Sah P, Fitzpatrick MC, et al. Evaluation of COVID-19 vaccination strategies with a delayed second dose. PLoS Biol. 2021;19(4):e3001211.","journal-title":"PLoS Biol"},{"key":"2321_CR8","doi-asserted-by":"publisher","first-page":"n1087","DOI":"10.1136\/bmj.n1087","volume":"373","author":"S Romero-Brufau","year":"2021","unstructured":"Romero-Brufau S, Chopra A, Ryu AJ, Gel E, Raskar R, Kremers W, et al. Public health impact of delaying second dose of BNT162b2 or mRNA-1273 covid-19 vaccine: simulation agent based modeling study. BMJ. 2021;373:n1087.","journal-title":"BMJ"},{"issue":"7","key":"2321_CR9","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1080\/14760584.2021.1925112","volume":"20","author":"M-X Zhang","year":"2021","unstructured":"Zhang M-X, Zhang T-T, Shi G-F, Cheng F-M, Zheng Y-M, Tung T-H, et al. Safety of an inactivated SARS-CoV-2 vaccine among healthcare workers in China. Expert Rev Vaccines. 2021;20(7):891\u20138.","journal-title":"Expert Rev Vaccines"},{"issue":"3","key":"2321_CR10","doi-asserted-by":"publisher","first-page":"249","DOI":"10.3390\/life11030249","volume":"11","author":"AG Mathioudakis","year":"2021","unstructured":"Mathioudakis AG, Ghrew M, Ustianowski A, Ahmad S, Borrow R, Papavasileiou LP, et al. Self-reported real-world safety and reactogenicity of COVID-19 vaccines: a vaccine recipient survey. Life. 2021;11(3):249.","journal-title":"Life"},{"issue":"1","key":"2321_CR11","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1038\/s41541-019-0132-6","volume":"4","author":"C Herv\u00e9","year":"2019","unstructured":"Herv\u00e9 C, Laup\u00e8ze B, Del Giudice G, Didierlaurent AM, Tavares Da Silva F. The how\u2019s and what\u2019s of vaccine reactogenicity. NPJ Vaccines. 2019;4(1):39.","journal-title":"NPJ Vaccines"},{"key":"2321_CR12","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1016\/j.ijid.2021.04.047","volume":"106","author":"RAK Kadali","year":"2021","unstructured":"Kadali RAK, Janagama R, Peruru S, Malayala SV. Side effects of BNT162b2 mRNA COVID-19 vaccine: a randomized, cross-sectional study with detailed self-reported symptoms from healthcare workers. Int J Infect Dis. 2021;106:376\u201381.","journal-title":"Int J Infect Dis"},{"issue":"12","key":"2321_CR13","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1001\/jama.2021.13443","volume":"326","author":"GA Diaz","year":"2021","unstructured":"Diaz GA, Parsons GT, Gering SK, Meier AR, Hutchinson IV, Robicsek A. Myocarditis and pericarditis after vaccination for COVID-19. JAMA. 2021;326(12):1210\u20132.","journal-title":"JAMA"},{"key":"2321_CR14","doi-asserted-by":"publisher","first-page":"108786","DOI":"10.1016\/j.clim.2021.108786","volume":"229","author":"M Garc\u00eda-Grimshaw","year":"2021","unstructured":"Garc\u00eda-Grimshaw M, Ceballos-Liceaga SE, Hern\u00e1ndez-Vanegas LE, N\u00fa\u00f1ez I, Hern\u00e1ndez-Valdivia N, Carrillo-Garc\u00eda DA, et al. Neurologic adverse events among 704,003 first-dose recipients of the BNT162b2 mRNA COVID-19 vaccine in Mexico: a nationwide descriptive study. Clin Immunol. 2021;229:108786.","journal-title":"Clin Immunol"},{"issue":"1","key":"2321_CR15","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/S1473-3099(21)00451-5","volume":"22","author":"EYF Wan","year":"2022","unstructured":"Wan EYF, Chui CSL, Lai FTT, Chan EWY, Li X, Yan VKC, et al. Bell\u2019s palsy following vaccination with mRNA (BNT162b2) and inactivated (CoronaVac) SARS-CoV-2 vaccines: a case series and nested case-control study. Lancet Infect Dis. 2022;22(1):64\u201372.","journal-title":"Lancet Infect Dis"},{"key":"2321_CR16","doi-asserted-by":"publisher","unstructured":"Fertel BS, Milk J, Simon EL, Muir MR, Smalley CM. COVID-19 vaccine adverse reactions bring patients to emergency departments. Am J Emerg Med. 2021. https:\/\/doi.org\/10.1016\/j.ajem.2021.05.013. Online ahead of print.","DOI":"10.1016\/j.ajem.2021.05.013"},{"issue":"6","key":"2321_CR17","doi-asserted-by":"publisher","first-page":"648","DOI":"10.3390\/vaccines9060648","volume":"9","author":"T Kim","year":"2021","unstructured":"Kim T, Park SY, Yu S, Park JW, Lee E, Jeon MH, et al. Impacts of side effects to BNT162b2 and the first dose of ChAdOx1 anti-SARS-CoV-2 vaccination on work productivity, the need for medical attention, and vaccine acceptance: a multicenter survey on healthcare workers in referral teaching hospitals in the Republic of Korea. Vaccines. 2021;9(6):648.","journal-title":"Vaccines"},{"issue":"8","key":"2321_CR18","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1016\/j.medj.2021.06.006","volume":"2","author":"R McMurry","year":"2021","unstructured":"McMurry R, Lenehan P, Awasthi S, Silvert E, Puranik A, Pawlowski C, et al. Real-time analysis of a mass vaccination effort confirms the safety of FDA-authorized mRNA COVID-19 vaccines. Med. 2021;2(8):965\u201378 e965.","journal-title":"Med"},{"issue":"4","key":"2321_CR19","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1136\/annrheumdis-2021-221571","volume":"81","author":"X Li","year":"2022","unstructured":"Li X, Tong X, Yeung WWY, Kuan P, Yum SHH, Chui CSL, et al. Two-dose COVID-19 vaccination and possible arthritis flare among patients with rheumatoid arthritis in Hong Kong. Ann Rheum Dis. 2022;81(4):564\u20138.","journal-title":"Ann Rheum Dis."},{"key":"2321_CR20","doi-asserted-by":"publisher","unstructured":"Chua GT, Kwan MYW, Chui CSL, Smith RD, Cheung EC, Tian T, et al. Epidemiology of acute myocarditis\/pericarditis in Hong Kong adolescents following Comirnaty vaccination. Clin Infect Dis. 2021. https:\/\/doi.org\/10.1093\/cid\/ciab989. Online ahead of print.","DOI":"10.1093\/cid\/ciab989"},{"issue":"1","key":"2321_CR21","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1038\/s41467-022-28068-3","volume":"13","author":"FTT Lai","year":"2022","unstructured":"Lai FTT, Huang L, Chui CSL, Wan EYF, Li X, Wong CKH, et al. Multimorbidity and adverse events of special interest associated with COVID-19 vaccines in Hong Kong. Nat Commun. 2022;13(1):411.","journal-title":"Nat Commun"},{"key":"2321_CR22","doi-asserted-by":"publisher","unstructured":"Lai FTT, Li X, Peng K, Huang L, Ip P, Tong X, et al. Carditis after COVID-19 vaccination with a messenger RNA vaccine and an inactivated virus vaccine: a case-control study. Ann Intern Med. 2022. https:\/\/doi.org\/10.7326\/M21-3700. Online ahead of print.","DOI":"10.7326\/M21-3700"},{"issue":"4","key":"2321_CR23","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1002\/ajh.26478","volume":"97","author":"CW Sing","year":"2022","unstructured":"Sing CW, Tang CTL, Chui CSL, Fan M, Lai FTT, Li X, et al. COVID-19 vaccines and risks of hematological abnormalities: nested case-control and self-controlled case series study. Am J Hematol. 2022;97(4):470\u201380.","journal-title":"Am J Hematol"},{"key":"2321_CR24","doi-asserted-by":"publisher","first-page":"100393","DOI":"10.1016\/j.lanwpc.2022.100393","volume":"21","author":"EYF Wan","year":"2022","unstructured":"Wan EYF, Chui CSL, Wang Y, Ng VWS, Yan VKC, Lai FTT, et al. Herpes zoster related hospitalization after inactivated (CoronaVac) and mRNA (BNT162b2) SARS-CoV-2 vaccination: a self-controlled case series and nested case-control study. Lancet Reg Health West Pac. 2022;21:100393.","journal-title":"Lancet Reg Health West Pac"},{"key":"2321_CR25","doi-asserted-by":"publisher","unstructured":"Lai FTT, Huang L, Peng K, Li X, Chui CSL, Wan EYF, et al. Post-COVID-19-vaccination adverse events and healthcare utilization among individuals with or without previous SARS-CoV-2 infection. J Intern Med. 2022. https:\/\/doi.org\/10.1111\/joim.13453. Online ahead of print.","DOI":"10.1111\/joim.13453"},{"key":"2321_CR26","doi-asserted-by":"publisher","unstructured":"Li X, Tong X, Wong ICK, Peng K, Chui CSL, Lai FTT, et al. Lack of inflammatory bowel disease flare-up following two-dose BNT162b2 vaccine: a population-based cohort study. Gut. 2022. https:\/\/doi.org\/10.1136\/gutjnl-2021-326860. Online ahead of print.","DOI":"10.1136\/gutjnl-2021-326860"},{"key":"2321_CR27","doi-asserted-by":"publisher","unstructured":"Xiong X, Wong CKH, Au ICH, Lai FTT, Li X, Wan EYF, et al. Safety of inactivated and mRNA COVID-19 vaccination among patients treated for hypothyroidism: a population-based cohort study. Thyroid. 2022. https:\/\/doi.org\/10.1089\/thy.2021.0684. Online ahead of print.","DOI":"10.1089\/thy.2021.0684"},{"key":"2321_CR28","unstructured":"The Government of the Hong Kong Special Administrative Region. Government announces 2019 COVID-19 vaccination programme. 2021. | Press Release | https:\/\/www.info.gov.hk\/gia\/general\/202102\/18\/P2021021800767.htm?fontSize=1. Accessed 25 Jan 2022."},{"key":"2321_CR29","unstructured":"The Government of the Hong Kong Special Administrative Region. Government expands scope of priority groups and opens more CVCs. 2021. | Press Release | https:\/\/www.info.gov.hk\/gia\/general\/202102\/18\/P2021021800767.htm?fontSize=1. Accessed 25 Jan 2022."},{"key":"2321_CR30","unstructured":"The Government of the Hong Kong Special Administrative Region. Vaccination priority groups to be expanded to cover people aged 30 or above. 2021. | Press Release | https:\/\/www.info.gov.hk\/gia\/general\/202103\/15\/P2021031500626.htm?fontSize=1. Accessed 25 Jan 2022."},{"key":"2321_CR31","unstructured":"The Government of the Hong Kong Special Administrative Region. COVID-19 Vaccination Programme opens to persons aged 16 or above. 2021. | Press Release | https:\/\/www.info.gov.hk\/gia\/general\/202104\/15\/P2021041500565.htm?fontSize=1. Accessed 25 Jan 2022."},{"key":"2321_CR32","unstructured":"The Government of the Hong Kong Special Administrative Region. Secretary for Food and Health approves lowering age limit for receiving Comirnaty vaccine. 2021. | Press Release | https:\/\/www.info.gov.hk\/gia\/general\/202106\/03\/P2021060300652.htm?fontSize=1. Accessed 25 Jan 2022."},{"key":"2321_CR33","unstructured":"Centre for Health Protection. Consensus interim recommendations on the use of COVID-19 vaccines in Hong Kong. 2021. | Press Release | https:\/\/www.chp.gov.hk\/files\/pdf\/consensus_interim_recommendations_on_the_use_of_covid19_vaccines_inhk.pdf. Accessed 25 Jan 2022."},{"issue":"27","key":"2321_CR34","doi-asserted-by":"publisher","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","volume":"383","author":"FP Polack","year":"2020","unstructured":"Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine. N Engl J Med. 2020;383(27):2603\u201315.","journal-title":"N Engl J Med"},{"issue":"10296","key":"2321_CR35","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/S0140-6736(21)01429-X","volume":"398","author":"MD Tanriover","year":"2021","unstructured":"Tanriover MD, Doganay HL, Akova M, Guner HR, Azap A, Akhan S, et al. Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey. Lancet. 2021;398(10296):213\u201322.","journal-title":"Lancet"},{"key":"2321_CR36","unstructured":"The Sinovac-CoronaVac COVID-19 vaccine: what you need to know [https:\/\/www.who.int\/news-room\/feature-stories\/detail\/the-sinovac-covid-19-vaccine-what-you-need-to-know?gclid=CjwKCAjwvuGJBhB1EiwACU1AidX-t9s2okQDMmPxKmJ-pL9iAzrq0LZrTJbGcmQxmWAzgD6yCiJjbxoCZl4QAvD_BwE]. Accessed 28 Jan 2022."},{"key":"2321_CR37","doi-asserted-by":"publisher","first-page":"l5657","DOI":"10.1136\/bmj.l5657","volume":"367","author":"RJ Desai","year":"2019","unstructured":"Desai RJ, Franklin JM. Alternative approaches for confounding adjustment in observational studies using weighting based on the propensity score: a primer for practitioners. BMJ. 2019;367:l5657.","journal-title":"BMJ"},{"issue":"11","key":"2321_CR38","doi-asserted-by":"publisher","first-page":"389","DOI":"10.15585\/mmwr.mm7011e2","volume":"70","author":"JL Kriss","year":"2021","unstructured":"Kriss JL, Reynolds LE, Wang A, Stokley S, Cole MM, Harris LQ, et al. COVID-19 vaccine second-dose completion and interval between first and second doses among vaccinated persons - United States, December 14, 2020-February 14, 2021. MMWR Morb Mortal Wkly Rep. 2021;70(11):389\u201395.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2321_CR39","unstructured":"National Health Commission of the People\u2019s Republic of China. Novel coronavirus vaccine technical guide (first edition). 2021. | Press Release | http:\/\/www.nhc.gov.cn\/xcs\/yqfkdt\/202103\/c2febfd04fc5498f916b1be080905771.shtml. Accessed 16 Feb 2022."},{"key":"2321_CR40","volume-title":"The Bonferonni and `id\u00e1k corrections for multiple comparisons","author":"H Abdi","year":"2006","unstructured":"Abdi H. The Bonferonni and `id\u00e1k corrections for multiple comparisons; 2006."},{"issue":"1","key":"2321_CR41","doi-asserted-by":"publisher","first-page":"7217","DOI":"10.1038\/s41467-021-27410-5","volume":"12","author":"G Amirthalingam","year":"2021","unstructured":"Amirthalingam G, Bernal JL, Andrews NJ, Whitaker H, Gower C, Stowe J, et al. Serological responses and vaccine effectiveness for extended COVID-19 vaccine schedules in England. Nat Commun. 2021;12(1):7217.","journal-title":"Nat Commun"},{"issue":"10","key":"2321_CR42","doi-asserted-by":"publisher","first-page":"3310","DOI":"10.1080\/21645515.2021.1945902","volume":"17","author":"J Li","year":"2021","unstructured":"Li J, Chen W, Chen M, Bai S, Yuan Q, Wu J. Immunogenicity of inactivated COVID-19 vaccines at different vaccination intervals. Hum Vaccines Immunother. 2021;17(10):3310\u20133.","journal-title":"Hum Vaccines Immunother."},{"issue":"1","key":"2321_CR43","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1038\/s41541-022-00432-w","volume":"7","author":"H Parry","year":"2022","unstructured":"Parry H, Bruton R, Stephens C, Bentley C, Brown K, Amirthalingam G, et al. Extended interval BNT162b2 vaccination enhances peak antibody generation. NPJ Vaccines. 2022;7(1):14.","journal-title":"NPJ Vaccines"},{"issue":"23","key":"2321_CR44","doi-asserted-by":"publisher","first-page":"5699","DOI":"10.1016\/j.cell.2021.10.011","volume":"184","author":"RP Payne","year":"2021","unstructured":"Payne RP, Longet S, Austin JA, Skelly DT, Dejnirattisai W, Adele S, et al. Immunogenicity of standard and extended dosing intervals of BNT162b2 mRNA vaccine. Cell. 2021;184(23):5699\u2013714 e5611.","journal-title":"Cell"},{"issue":"1","key":"2321_CR45","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1186\/s40249-021-00878-5","volume":"10","author":"M Chen","year":"2021","unstructured":"Chen M, Yuan Y, Zhou Y, Deng Z, Zhao J, Feng F, et al. Safety of SARS-CoV-2 vaccines: a systematic review and meta-analysis of randomized controlled trials. Infect Dis Poverty. 2021;10(1):94.","journal-title":"Infect Dis Poverty"},{"issue":"1","key":"2321_CR46","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s13037-021-00291-9","volume":"15","author":"P Anand","year":"2021","unstructured":"Anand P, Stahel VP. The safety of COVID-19 mRNA vaccines: a review. Patient Saf Surg. 2021;15(1):20.","journal-title":"Patient Saf Surg"},{"issue":"7","key":"2321_CR47","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/S1473-3099(21)00224-3","volume":"21","author":"C Menni","year":"2021","unstructured":"Menni C, Klaser K, May A, Polidori L, Capdevila J, Louca P, et al. Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID Symptom Study app in the UK: a prospective observational study. Lancet Infect Dis. 2021;21(7):939\u201349.","journal-title":"Lancet Infect Dis"},{"issue":"40","key":"2321_CR48","doi-asserted-by":"publisher","first-page":"5963","DOI":"10.1016\/j.vaccine.2021.07.067","volume":"39","author":"A Michos","year":"2021","unstructured":"Michos A, Tatsi EB, Filippatos F, Dellis C, Koukou D, Efthymiou V, et al. Association of total and neutralizing SARS-CoV-2 spike -receptor binding domain antibodies with epidemiological and clinical characteristics after immunization with the 1(st) and 2(nd) doses of the BNT162b2 vaccine. Vaccine. 2021;39(40):5963\u20137.","journal-title":"Vaccine"},{"key":"2321_CR49","doi-asserted-by":"publisher","first-page":"100914","DOI":"10.1016\/j.eclinm.2021.100914","volume":"36","author":"A d\u2019Arminio Monforte","year":"2021","unstructured":"d\u2019Arminio Monforte A, Tavelli A, Perrone PM, Za A, Razzini K, Tomasoni D, et al. Association between previous infection with SARS CoV-2 and the risk of self-reported symptoms after mRNA BNT162b2 vaccination: data from 3,078 health care workers. EClinicalMedicine. 2021;36:100914.","journal-title":"EClinicalMedicine"},{"issue":"6","key":"2321_CR50","doi-asserted-by":"publisher","first-page":"553","DOI":"10.3390\/vaccines9060553","volume":"9","author":"M Nittner-Marszalska","year":"2021","unstructured":"Nittner-Marszalska M, Rosiek-Biegus M, Kope\u0107 A, Paw\u0142owicz R, Kosi\u0144ska M, \u0141ata A, et al. Pfizer-BioNTech COVID-19 vaccine tolerance in allergic versus non-allergic individuals. Vaccines. 2021;9(6):553.","journal-title":"Vaccines"},{"key":"2321_CR51","doi-asserted-by":"publisher","unstructured":"Ossato A, Tessari R, Trabucchi C, Zuppini T, Realdon N, Marchesini F. Comparison of medium-term adverse reactions induced by the first and second dose of mRNA BNT162b2 (Comirnaty, Pfizer-BioNTech) vaccine: a post-marketing Italian study conducted between 1 January and 28 February 2021. Eur J Hosp Pharm. 2021. https:\/\/doi.org\/10.1136\/ejhpharm-2021-002933. Online ahead of print.","DOI":"10.1136\/ejhpharm-2021-002933"},{"issue":"10","key":"2321_CR52","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1001\/jamacardio.2021.2821","volume":"6","author":"DK Shay","year":"2021","unstructured":"Shay DK, Shimabukuro TT, DeStefano F. Myocarditis occurring after immunization with mRNA-based COVID-19 vaccines. JAMA Cardiol. 2021;6(10):1115\u20137.","journal-title":"JAMA Cardiol"},{"issue":"2","key":"2321_CR53","doi-asserted-by":"publisher","first-page":"100517","DOI":"10.1016\/j.waojou.2021.100517","volume":"14","author":"PJ Turner","year":"2021","unstructured":"Turner PJ, Ansotegui IJ, Campbell DE, Cardona V, Ebisawa M, El-Gamal Y, et al. COVID-19 vaccine-associated anaphylaxis: a statement of the World Allergy Organization Anaphylaxis Committee. World Allergy Organ J. 2021;14(2):100517.","journal-title":"World Allergy Organ J"},{"issue":"10277","key":"2321_CR54","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1016\/S0140-6736(21)00455-4","volume":"397","author":"JFR Robertson","year":"2021","unstructured":"Robertson JFR, Sewell HF, Stewart M. Delayed second dose of the BNT162b2 vaccine: innovation or misguided conjecture? Lancet. 2021;397(10277):879\u201380.","journal-title":"Lancet"},{"key":"2321_CR55","doi-asserted-by":"publisher","unstructured":"Bueno SM, Abarca K, Gonz\u00e1lez PA, G\u00e1lvez NMS, Soto JA, Duarte LF, et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine in a subgroup of healthy adults in Chile. Clin Infect Dis. 2021. https:\/\/doi.org\/10.1093\/cid\/ciab823. Online ahead of print.","DOI":"10.1093\/cid\/ciab823"},{"key":"2321_CR56","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/21645515.2021.1953344","volume":"17","author":"A Soysal","year":"2021","unstructured":"Soysal A, G\u00f6n\u00fcll\u00fc E, Karabay\u0131r N, Alan S, At\u0131c\u0131 S, Y\u0131ld\u0131z \u0130, et al. Comparison of immunogenicity and reactogenicity of inactivated SARS-CoV-2 vaccine (CoronaVac) in previously SARS-CoV-2 infected and uninfected health care workers. Hum Vaccin Immunother. 2021;17:1\u20135.","journal-title":"Hum Vaccin Immunother"},{"issue":"6","key":"2321_CR57","doi-asserted-by":"publisher","first-page":"100967","DOI":"10.1016\/j.accpm.2021.100967","volume":"40","author":"P Loubet","year":"2021","unstructured":"Loubet P, Laureillard D, Martin A, Larcher R, Sotto A. Why promoting a COVID-19 vaccine booster dose? Anaesth Crit Care Pain Med. 2021;40(6):100967.","journal-title":"Anaesth Crit Care Pain Med"},{"key":"2321_CR58","doi-asserted-by":"publisher","unstructured":"P\u00e9rez-Then E, Lucas C, Monteiro VS, Miric M, Brache V, Cochon L, et al. Neutralizing antibodies against the SARS-CoV-2 Delta and Omicron variants following heterologous CoronaVac plus BNT162b2 booster vaccination. Nat Med. 2022. https:\/\/doi.org\/10.1038\/s41591-022-01705-6. Online ahead of print.","DOI":"10.1038\/s41591-022-01705-6"},{"issue":"26","key":"2321_CR59","doi-asserted-by":"publisher","first-page":"2421","DOI":"10.1056\/NEJMoa2115926","volume":"385","author":"YM Bar-On","year":"2021","unstructured":"Bar-On YM, Goldberg Y, Mandel M, Bodenheimer O, Freedman L, Alroy-Preis S, et al. Protection against COVID-19 by BNT162b2 booster across age groups. N Engl J Med. 2021;385(26):2421\u201330.","journal-title":"N Engl J Med"},{"issue":"10316","key":"2321_CR60","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1016\/S0140-6736(21)02249-2","volume":"398","author":"N Barda","year":"2021","unstructured":"Barda N, Dagan N, Cohen C, Hern\u00e1n MA, Lipsitch M, Kohane IS, et al. Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study. Lancet. 2021;398(10316):2093\u2013100.","journal-title":"Lancet"},{"key":"2321_CR61","doi-asserted-by":"crossref","unstructured":"Gardner BJ, Kilpatrick AM. Third doses of COVID-19 vaccines reduce infection and transmission of SARS-CoV-2 and could prevent future surges in some populations: a modeling study. medRxiv. 2021; 2021.2010.2025.21265500. (medRxiv preprint).","DOI":"10.1101\/2021.10.25.21265500"},{"issue":"1","key":"2321_CR62","doi-asserted-by":"publisher","first-page":"2101114","DOI":"10.2807\/1560-7917.ES.2022.27.1.2101114","volume":"27","author":"G Ireland","year":"2022","unstructured":"Ireland G, Whitaker H, Ladhani SN, Baawuah F, Subbarao S, Linley E, et al. Serological responses to COVID-19 Comirnaty booster vaccine, London, United Kingdom, September to December 2021. Euro Surveill. 2022;27(1):2101114.","journal-title":"Euro Surveill"},{"issue":"10318","key":"2321_CR63","doi-asserted-by":"publisher","first-page":"2258","DOI":"10.1016\/S0140-6736(21)02717-3","volume":"398","author":"APS Munro","year":"2021","unstructured":"Munro APS, Janani L, Cornelius V, Aley PK, Babbage G, Baxter D, et al. Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial. Lancet. 2021;398(10318):2258\u201376.","journal-title":"Lancet"},{"issue":"10324","key":"2321_CR64","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/S0140-6736(22)00094-0","volume":"399","author":"SA Costa Clemens","year":"2022","unstructured":"Costa Clemens SA, Weckx L, Clemens R, Almeida Mendes AV, Ramos Souza A, Silveira MBV, et al. Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study. Lancet. 2022;399(10324):521\u20139.","journal-title":"Lancet"},{"issue":"2","key":"2321_CR65","doi-asserted-by":"publisher","first-page":"160","DOI":"10.3390\/vaccines10020160","volume":"10","author":"K-W Khong","year":"2022","unstructured":"Khong K-W, Liu D, Leung K-Y, Lu L, Lam H-Y, Chen L, et al. Antibody response of combination of BNT162b2 and CoronaVac platforms of COVID-19 vaccines against omicron variant. Vaccines. 2022;10(2):160.","journal-title":"Vaccines"},{"key":"2321_CR66","doi-asserted-by":"publisher","first-page":"102246","DOI":"10.1016\/j.tmaid.2021.102246","volume":"45","author":"NA Khan","year":"2022","unstructured":"Khan NA, Al-Thani H, El-Menyar A. The emergence of new SARS-CoV-2 variant (omicron) and increasing calls for COVID-19 vaccine boosters-the debate continues. Travel Med Infect Dis. 2022;45:102246.","journal-title":"Travel Med Infect Dis"}],"container-title":["BMC Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-022-02321-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12916-022-02321-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-022-02321-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,24]],"date-time":"2022-10-24T19:09:57Z","timestamp":1666638597000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmedicine.biomedcentral.com\/articles\/10.1186\/s12916-022-02321-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,17]]},"references-count":66,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["2321"],"URL":"https:\/\/doi.org\/10.1186\/s12916-022-02321-4","relation":{},"ISSN":["1741-7015"],"issn-type":[{"value":"1741-7015","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,17]]},"assertion":[{"value":"15 October 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 March 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 March 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Institutional Review Board of the University of Hong Kong\/Hospital Authority Hong Kong West Cluster (UW 21-149 and UW 21-138) and the Department of Health Ethics Committee (LM 21\/2021). All data were anonymized, and the project was granted a waiver of participant consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"CKHW reports receipt of research funding from the EuroQoL Group Research Foundation, the Hong Kong Research Grants Council, and the Hong Kong Health and Medical Research Fund. FTTL has been supported by the RGC Postdoctoral Fellowship under the Hong Kong Research Grants Council, outside the submitted work. XL has received research grants from the Food and Health Bureau of the Government of the Hong Kong SAR, research and educational grants from Janssen and Pfizer, internal funding from the University of Hong Kong, and consultancy fee from Merck Sharp & Dohme, unrelated to this work. CSLC has received grants from the Food and Health Bureau of the Hong Kong Government, Hong Kong Research Grant Council, Hong Kong Innovation and Technology Commission, Pfizer, IQVIA, and Amgen and personal fee from Primevigilance Ltd., outside the submitted work. EWYC reports honorarium from Hospital Authority, grants from Research Grants Council (RGC, Hong Kong), grants from Research Fund Secretariat of the Food and Health Bureau, grants from National Natural Science Fund of China, grants from Wellcome Trust, grants from Bayer, grants from Bristol-Myers Squibb, grants from Pfizer, grants from Janssen, grants from Amgen, grants from Takeda, and grants from Narcotics Division of the Security Bureau of HKSAR, outside the submitted work. EYFW has received research grants from the Food and Health Bureau of the Government of the Hong Kong SAR and the Hong Kong Research Grants Council, outside the submitted work. BJC reports support paid to their institution from HMRF, RGC, NIH, CDC, NIAID, ITC, Wellcome, and WHO and is supported by the AIR@innoHK program of the Innovation and Technology Commission of the Hong Kong SAR Government, all outside the submitted work. ICKW reports research funding outside the submitted work from Amgen, Bristol-Myers Squibb, Pfizer, Janssen, Bayer, GSK, Novartis, the Hong Kong RGC, the Hong Kong Health and Medical Research Fund, National Institute for Health Research in England, European Commission, and National Health and Medical Research Council in Australia and also received speaker fees from Janssen and Medicine in the previous 3 years, all outside the submitted work.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"119"}}